StreetInsider.com News Articles

Zentalis reports overall survival data for ovarian cancer drug at ESMO

Fri, 23 Oct 2026 10:16:15 -0400

Zentalis Pharmaceuticals (Nasdaq: ZNTL) presented interim analysis results from its DENALI Part 1b clinical trial at the European Society for Medical Oncology Congress 2026 in Madrid, Spain, including the first overall survival data for its investigational drug azenosertib.

The data, based on a May 22, 2026 cutoff, showed a median overall survival of 15.9 months in Cyclin E1-positive platinum-resistant ovarian cancer patients who had received between one and five prior lines of therapy. By comparison, Cyclin E1-negative patients had a median overall survival of 7.5 months.

The trial enrolled 102 patients, with 94 evaluable for Cyclin E1 status. Of those, 48 were

Zentalis reports overall survival data for ovarian cancer drug at ESMO

Fri, 23 Oct 2026 10:16:15 -0400

The trial enrolled 102 patients, with 94 evaluable for Cyclin E1 status. Of those, 48 were

Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026

Fri, 23 Oct 2026 10:15:00 -0400

Median overall survival of 15.9 months in Cyclin E1-positive PROC, with 1–5 prior lines of therapy; safety profile in DENALI Part 1b was consistent with prior reporting
Median relative dose intensity was 84.6%, confirming high overall exposure to azenosertib
DENALI Part 1b interim analysis adds to the body of evidence supporting Cyclin E1 protein expression as a predictive biomarker for azenosertib in platinum-resistant ovarian cancer

SAN DIEGO, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven

Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026

Fri, 23 Oct 2026 10:15:00 -0400

Median overall survival of 15.9 months in Cyclin E1-positive PROC, with 1–5 prior lines of therapy; safety profile in DENALI Part 1b was consistent with prior reporting
Median relative dose intensity was 84.6%, confirming high overall exposure to azenosertib
DENALI Part 1b interim analysis adds to the body of evidence supporting Cyclin E1 protein expression as a predictive biomarker for azenosertib in platinum-resistant ovarian cancer

H.C. Wainwright Reiterates Buy Rating on Zentalis Pharmaceuticals (ZNTL)

Mon, 19 Oct 2026 08:08:29 -0400

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $10.00 price target on Zentalis Pharmaceuticals (NASDAQ: ZNTL).

The analyst commented: "Yesterday, Zentalis announced via ESMO 2026 abstract interim OS data from DENALI Part 1b where cyclin E1-positive (n=48) patients achieved a mOS of 15.8 months (95% CI, 8.7-17.8). These data position azenosertib squarely within the discussion of biomarker-selective agents like mirvetuximab (ABBV, not rated), where FRα-high patients achieved a mOS of 16.85 months versus 13.34 months with chemotherapy in the final Phase 3 MIRASOL analysis. While differences in patient selection and study design preclude direct comparisons, we view the survival

Zentalis reports survival data for azenosertib in ovarian cancer trial

Mon, 19 Oct 2026 06:02:34 -0400

Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced interim overall survival data from the DENALI Part 1b study of its investigational WEE1 inhibitor azenosertib in patients with platinum-resistant ovarian cancer, according to a company press release.

The data, published in an abstract ahead of the European Society for Medical Oncology Congress 2026, showed a median overall survival of 15.8 months (95% CI, 8.7–17.8) in the Cyclin E1-positive subgroup of 48 patients, based on a September 2, 2025 data cutoff. The Cyclin E1-negative subgroup of 46 patients had a median overall survival of 7.5 months (95% CI, 5.8–12.3). No new safety signals were observed.

DENALI Part

Zentalis reports survival data for azenosertib in ovarian cancer trial

Mon, 19 Oct 2026 06:02:34 -0400

DENALI Part

Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract

Sun, 18 Oct 2026 18:05:00 -0400

Median overall survival of 15.8 months in Cyclin E1-positive platinum-resistant ovarian cancer patients treated with azenosertib monotherapy
Data to be presented as a rapid oral presentation at ESMO Congress 2026 on October 23, 2026

SAN DIEGO, Oct. 18, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that overall survival (OS) data from an interim analysis of the DENALI Part 1b study (GOG-3066) have been published in the abstract for the upcoming rapid oral

Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract

Sun, 18 Oct 2026 18:05:00 -0400

Median overall survival of 15.8 months in Cyclin E1-positive platinum-resistant ovarian cancer patients treated with azenosertib monotherapy
Data to be presented as a rapid oral presentation at ESMO Congress 2026 on October 23, 2026

Premarket movers: Brazilian ADRs surge, Leslie’s plunges

Mon, 05 Oct 2026 07:25:25 -0400

Invezing.com - U.S. stock futures pointed lower on Monday, signaling a cautious start to the trading week as investors kept tabs on bond-market jitters and the outlook for Federal Reserve interest rates.

By 06:08 ET (10:08 GMT), the Dow futures contract had fallen 92 points, or 0.2%, S&P 500 futures had dropped 13 points, or 0.2%, and Nasdaq 100 futures had dipped 69 points, or 0.2%.

Here are some of the biggest premarket U.S. stock movers today:

Shares of Group 1 Automotive fell 2.1% after Morgan Stanley downgraded the stock to Underweight from Equalweight and cut its price target to $232 from $300.

Analyst

Premarket movers: Brazilian ADRs surge, Leslie’s plunges

Mon, 05 Oct 2026 07:25:25 -0400

By 06:08 ET (10:08 GMT), the Dow futures contract had fallen 92 points, or 0.2%, S&P 500 futures had dropped 13 points, or 0.2%, and Nasdaq 100 futures had dipped 69 points, or 0.2%.

Here are some of the biggest premarket U.S. stock movers today:

Shares of Group 1 Automotive fell 2.1% after Morgan Stanley downgraded the stock to Underweight from Equalweight and cut its price target to $232 from $300.

Analyst

Premarket movers: Brazilian ADRs surge, Leslie’s plunges

Mon, 05 Oct 2026 07:25:25 -0400

By 06:08 ET (10:08 GMT), the Dow futures contract had fallen 92 points, or 0.2%, S&P 500 futures had dropped 13 points, or 0.2%, and Nasdaq 100 futures had dipped 69 points, or 0.2%.

Here are some of the biggest premarket U.S. stock movers today:

Shares of Group 1 Automotive fell 2.1% after Morgan Stanley downgraded the stock to Underweight from Equalweight and cut its price target to $232 from $300.

Analyst

Leerink Assumes Zentalis Pharmaceuticals (ZNTL) at Outperform

Mon, 05 Oct 2026 06:44:29 -0400

Leerink analyst Asthika Goonewardene assumes coverage on Zentalis Pharmaceuticals (NASDAQ: ZNTL) with a Outperform rating and a price target of $8.00.

For an analyst ratings summary and ratings history on Zentalis Pharmaceuticals click here. For more ratings news on Zentalis Pharmaceuticals click here.

Shares of Zentalis Pharmaceuticals closed at $2.52 yesterday.

Form 4 Zentalis Pharmaceuticals For: Sep 30 Filed by: Bruns Ingmar

Thu, 01 Oct 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20261001/27137252.html

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 01 Oct 2026 17:10:00 -0400

SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on October 1, 2026, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 62,000 shares of the Company’s common stock to three (3) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual’s

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 01 Oct 2026 17:10:00 -0400

Wells Fargo Assumes Zentalis Pharmaceuticals (ZNTL) at Equal Weight

Wed, 30 Sep 2026 06:23:27 -0400

Wells Fargo analyst Yanan Zhu assumes coverage on Zentalis Pharmaceuticals (NASDAQ: ZNTL) with a Equal Weight rating and a price target of $5.00.

For an analyst ratings summary and ratings history on Zentalis Pharmaceuticals click here. For more ratings news on Zentalis Pharmaceuticals click here.

Shares of Zentalis Pharmaceuticals closed at $2.72 yesterday.

William Blair Starts Zentalis Pharmaceuticals (ZNTL) at Outperform

Tue, 15 Sep 2026 16:09:06 -0400

William Blair analyst Matt Phipps initiates coverage on Zentalis Pharmaceuticals (NASDAQ: ZNTL) with a Outperform rating.

The analyst comments "We are initiating coverage of Zentalis Pharmaceuticals based on the potential of the WEE1 inhibitor, azenosertib, to deliver a clinically meaningful overall response rate (ORR) in the ongoing DENALI trial, supporting accelerated approval for the treatment of Cyclin E1+ platinum-resistant ovarian cancer (PROC) patients. We believe azenosertib’s improved selectivity for WEE1 addresses key limitations of AstraZeneca’s first-generation WEE1 inhibitor, adavosertib, which inhibited WEE1 and the related kinase PLK1 with comparable potency, contributing to tolerability issues and its ultimate discontinuation. Azenosertib’s greater kinase

William Blair Starts Zentalis Pharmaceuticals (ZNTL) at Outperform

Tue, 15 Sep 2026 16:09:06 -0400

William Blair analyst Matt Phipps initiates coverage on Zentalis Pharmaceuticals (NASDAQ: ZNTL) with a Outperform rating.

Form SCHEDULE 13G/A Zentalis Pharmaceuticals Filed by: WALTERS GROUP

Wed, 19 Aug 2026 18:13:00 -0400

si-local-file:///var/storage/secattach/20260819/26951382.html

Form SCHEDULE 13G/A Zentalis Pharmaceuticals Filed by: WALTERS GROUP

Wed, 19 Aug 2026 18:13:00 -0400

si-local-file:///var/storage/secattach/20260819/26951382.html

Form 4 Zentalis Pharmaceuticals For: Aug 14 Filed by: WALTERS GROUP

Wed, 19 Aug 2026 18:11:00 -0400

si-local-file:///var/storage/secattach/20260819/26951380.html

Form 4 Zentalis Pharmaceuticals For: Aug 14 Filed by: WALTERS GROUP

Wed, 19 Aug 2026 18:11:00 -0400

si-local-file:///var/storage/secattach/20260819/26951380.html

Zentalis closes $92.6M public offering of common stock

Mon, 17 Aug 2026 16:01:14 -0400

Zentalis Pharmaceuticals (Nasdaq: ZNTL) closed an underwritten public offering of 26,450,000 shares of common stock at $3.50 per share, generating approximately $92.6 million in gross proceeds before deducting underwriting discounts, commissions, and offering expenses, according to a press release.

The share count includes 3,450,000 shares sold through the full exercise of the underwriters' option to purchase additional shares. All shares were sold by the company.

Zentalis said it intends to use the net proceeds, combined with existing cash, cash equivalents, and marketable securities, to fund clinical trials, preclinical studies, regulatory filings, manufacturing, and companion diagnostic development, as well as pre-commercial activities, capital

Zentalis closes $92.6M public offering of common stock

Mon, 17 Aug 2026 16:01:14 -0400

The share count includes 3,450,000 shares sold through the full exercise of the underwriters' option to purchase additional shares. All shares were sold by the company.